In the April–June 2018 edition of Corporate Disputes, Dr. Gregory K. Bell discusses recent litigation involving companies operating in the pharmaceutical and medical device sector and the factors driving them. In this roundtable discussion, the panel experts explain the main issues and challenges these types of companies face during the litigation process. To read the article, click the download button to the right.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.